This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (2)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in this journal  Topic Collections  • Oncology  • Skin Cancer  • Dermatology  • Dermatologic Disorders  • Neoplasms  • Dermatology, Other  • Drug Therapy  • Drug Therapy, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

Kenneth Y. Tsai, MD, PhD

Arch Dermatol. 2007;143(6):779-782.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Commentary on: Systematic review of systemic adjuvant therapy for patients at high risk for recurrent melanoma
Verma S, Quirt I, McCready D, Bak K, Charette M, Iscoe N
Cancer. 2006;106:1431-1442

Question: What is the evidence that systemic adjuvant therapy is of benefit in patients with high-risk resected melanoma? In their study, Verma et al include patients with thick melanomas (at least 4.0 mm in thickness), Clark level V tumor, primary melanoma with in-transit metastases, primary melanoma with clinically apparent lymph node involvement or a positive sentinel lymph node biopsy result, resected lymph node disease with no known primary site, and current American Joint Committee on Cancer (AJCC) 2002 stage IIB, IIC, and III disease.

Data Sources: The MEDLINE, CANCERLIT, EMBASE, and Cochrane Library databases were searched for articles published between 1980 and 2004, as were American Society of Clinical Oncology proceedings (1996-2004) detailing ongoing . . . [Full Text of this Article]

Comment


AUTHOR INFORMATION
Department of Dermatology, Harvard Medical School, Boston, Mass

CiteULike    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLES

Cloud Over Sentinel Node Biopsy: Unlikely Survival Benefit in Melanoma
Urbà González
Arch Dermatol. 2007;143(6):775-776.
EXTRACT | FULL TEXT  

The Current Status of Evaluation and Treatment of High-Risk Cutaneous Melanoma: Therapeutic Breakthroughs Remain Elusive
Matthew H. Kanzler
Arch Dermatol. 2007;143(6):785-787.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

The Current Status of Evaluation and Treatment of High-Risk Cutaneous Melanoma: Therapeutic Breakthroughs Remain Elusive
Kanzler
Arch Dermatol 2007;143:785-787.
FULL TEXT